
Need professional-grade analysis? Visit stockanalysis.com
$3.03T
N/A
N/A
157.00%
Johnson & Johnson (JNJB34) trades on SA in BRL. The company is classified in the Healthcare sector under the Drug Manufacturers - General industry. The stock currently trades at BRL75.72, down 1.02% from the previous close.
Over the past year, JNJB34 has traded between a low of BRL53.84 and a high of BRL86.45. The stock has gained 31.6% over this period. It is currently 12.4% below its 52-week high.
Johnson & Johnson has a market capitalization of $3.03T and a dividend yield of 157.00%.
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Side-by-side comparison against top Healthcare peers.